Geneva, March 23 -- International Clinical Trials Registry received information related to the study (ChiCTR2600120221) titled 'A Multicenter, Open-Label, Randomized, Phase II Clinical Trial of Trastuzumab Rezetecan-based Therapy for Brain Metastases in HER2-Positive Breast Cancer' on March 11.
Study Type: Interventional study
Study Design:
Parallel
Primary Sponsor: ChongQing university cancer hospital
Condition:
Breast cancer
Intervention:
Group A:Trastuzumab Rezetecan for Injection 4.8mg/kg,ivgtt,q3w
Group B:Trastuzumab Rezetecan for Injection 4.8mg/kg,ivgtt,q3w
pyrotinib 320mg po qd
Group C:Trastuzumab Rezetecan for Injection 4.8mg/kg,ivgtt,q3w
anlotinib 12mg po d1-14,q3w
Group D:Trastuzumab Rezetecan for Injection 4.8mg/kg,i...